Cefepime free base | CAS# 88040-23-7 | antibiotic

MedKoo Cat#: 584231 | Name: Cefepime free base

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefepime is a fourth-generation cephalosporin antibiotic. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both types of organism than third-generation agents. Cefepime is a broad-spectrum cephalosporin antibiotic and has been used to treat bacteria responsible for causing pneumonia and infections of the skin and urinary tract. Some of these bacteria include Pseudomonas, Escherichia, and Streptococcus species.

Chemical Structure

Cefepime free base

CAS#88040-23-7 (free base)

Theoretical Analysis

MedKoo Cat#: 584231

Name: Cefepime free base

CAS#: 88040-23-7 (free base)

Chemical Formula: C19H24N6O5S2

Exact Mass: 480.1250

Molecular Weight: 480.56

Elemental Analysis: C, 47.49; H, 5.03; N, 17.49; O, 16.65; S, 13.34

Price and Availability

Size	Price	Availability
50mg	USD 350.00	2 Weeks
100mg	USD 550.00	2 Weeks
500mg	USD 1,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

103296-32-8 (compound E) 123171-59-5 (2HCl hydrate) 88040-23-7 (free base) 107648-78-2 (sulfate) 107648-80-6 (2HCl)

Synonym

Cefepime; Maxipime; Cefepima; Cefepimum

IUPAC/Chemical Name

Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, hydroxide, inner salt, (6R-(6alpha,7beta(Z)))-

InChi Key

HVFLCNVBZFFHBT-ZKDACBOMSA-N

InChi Code

InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1

SMILES Code

C[N+]1(CC(CS[C@]2([H])[C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)=C(C([O-])=O)N2C3=O)CCCC1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Cefepime is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria.

In vitro activity:

Cefepime is an extended-spectrum parenteral cephalosporin antibiotic active in vitro against a broad spectrum of gram-positive and gram-negative aerobic bacteria. Cefepime has a decreased propensity to induce beta-lactamases compared with other beta-lactam antibiotics. Reference: Am J Med. 1996 Jun 24;100(6A):68S-75S. https://linkinghub.elsevier.com/retrieve/pii/S0002-9343(96)00110-6

In vivo activity:

Cefepime has a pharmacokinetic disposition similar to that of other renally eliminated cephalosporins, with a half-life of approximately 2 hours. Cefepime has demonstrated clinical efficacy against a variety of infections, including urinary tract infections, pneumonia, and skin and skin structure infections. Cefepime is generally well tolerated Reference: Ann Pharmacother. 1996 Dec;30(12):1414-24. https://journals.sagepub.com/doi/10.1177/106002809603001211?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Preparing Stock Solutions

The following data is based on the product molecular weight 480.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

In vitro protocol:

1. Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med. 1996 Jun 24;100(6A):68S-75S. doi: 10.1016/s0002-9343(96)00110-6. PMID: 8678100.

In vivo protocol:

1. Wynd MA, Paladino JA. Cefepime: a fourth-generation parenteral cephalosporin. Ann Pharmacother. 1996 Dec;30(12):1414-24. doi: 10.1177/106002809603001211. PMID: 8968455.

1: Ajibola O, Aremu TO, Dada SO, Ajibola O, Adeyinka KO, Ajibola A, Oluwole OE. The Trend of Cefepime-Induced Neurotoxicity: A Systematic Review. Cureus. 2023 Jun 26;15(6):e40980. doi: 10.7759/cureus.40980. PMID: 37503476; PMCID: PMC10370502. 2: Jean-Michel V, Homey C, Devos P, Delannoy PY, Boussekey N, Caulier T, Leroy O, Georges H. Continuous Infusion of High Doses of Cefepime in Intensive Care Unit: Assessment of Steady-State Plasma Level and Incidence on Neurotoxicity. Antibiotics (Basel). 2022 Dec 30;12(1):69. doi: 10.3390/antibiotics12010069. PMID: 36671270; PMCID: PMC9854724. 3: Al Kamaly O. Review on Characterization, Properties, and Analytical Methods of Cefepime. Int J Anal Chem. 2022 Jun 29;2022:6909528. doi: 10.1155/2022/6909528. PMID: 35814263; PMCID: PMC9259364. 4: Pais GM, Chang J, Barreto EF, Stitt G, Downes KJ, Alshaer MH, Lesnicki E, Panchal V, Bruzzone M, Bumanglag AV, Burke SN, Scheetz MH. Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. Clin Pharmacokinet. 2022 Jul;61(7):929-953. doi: 10.1007/s40262-022-01137-y. Epub 2022 Jun 29. PMID: 35764774; PMCID: PMC9345683. 5: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Cefepime. 2022 Apr 18. PMID: 30000393. 6: Nguyen DD, Lai S. Prolonged Cefepime-Induced Neurotoxicity in a Patient with End-Stage Renal Disease. Am J Case Rep. 2022 Jan 24;23:e934083. doi: 10.12659/AJCR.934083. PMID: 35067669; PMCID: PMC8800466. 7: Su CY, Lin WH. Cefepime Induced Neurotoxicity Mimicking Clinical Presentation of Left Middle Cerebral Artery Infarction: A Case Report and Review of Literature. Acta Neurol Taiwan. 2022 Jan 25;31(1):41-45. PMID: 34988953. 8: Muradbegovic J, Leidi A, Serratrice J. Encéphalopathie au céfépime [Cefepime- induced encephalopathy]. Rev Med Suisse. 2019 Nov 27;15(673):2210-2212. French. PMID: 31778052. 9: McDonald D, Shah P. Cefepime Dosing in Neonates: What is the Evidence? Am J Perinatol. 2021 Jun;38(7):657-661. doi: 10.1055/s-0039-3400312. Epub 2019 Nov 27. PMID: 31777048. 10: Bechashk SM, Moradi G, Mohsenpour B, Ramazanzadeh R. Prevalence of Cefepime- Resistant Escherichia coli in Iran: A Meta-Analysis (2007-2016). Iran J Public Health. 2019 Apr;48(4):603-611. PMID: 31110970; PMCID: PMC6500536. 11: Patel HB, Lusk KA, Cota JM. The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections. J Pharm Pract. 2019 Aug;32(4):458-463. doi: 10.1177/0897190017743134. Epub 2017 Nov 22. PMID: 29166830. 12: Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, Fraser GL. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017 Nov 14;21(1):276. doi: 10.1186/s13054-017-1856-1. PMID: 29137682; PMCID: PMC5686900. 13: Appa AA, Jain R, Rakita RM, Hakimian S, Pottinger PS. Characterizing Cefepime Neurotoxicity: A Systematic Review. Open Forum Infect Dis. 2017 Oct 10;4(4):ofx170. doi: 10.1093/ofid/ofx170. PMID: 29071284; PMCID: PMC5639733. 14: Toda Y, Yamazaki M, Ota T, Fujisawa Y, Kimura K. [A case of Cefepime encephalopathy, being difficult to distinguish from non-convulsive status epilepticus during the treatment of bacterial meningitis]. Rinsho Shinkeigaku. 2016 Oct 28;56(10):678-683. Japanese. doi: 10.5692/clinicalneurol.cn-000898. Epub 2016 Oct 28. Erratum in: Rinsho Shinkeigaku. 2016;56(11):788. PMID: 27680224. 15: Lindsay H, Gruner S, Brackett J. Cefepime-Induced Neurotoxicity Despite Dose Adjustment for Renal Disease: A Brief Report and Review of the Literature. J Pediatric Infect Dis Soc. 2017 Jun 1;6(2):199-201. doi: 10.1093/jpids/piw022. PMID: 27147713. 16: Burgess SV, Mabasa VH, Chow I, Ensom MH. Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review. Ann Pharmacother. 2015 Mar;49(3):311-22. doi: 10.1177/1060028014564179. Epub 2015 Jan 9. PMID: 25575975. 17: Mani LY, Kissling S, Viceic D, Vogt B, Burnier M, Buclin T, Renard D. Intermittent hemodialysis treatment in cefepime-induced neurotoxicity: case report, pharmacokinetic modeling, and review of the literature. Hemodial Int. 2015 Apr;19(2):333-43. doi: 10.1111/hdi.12198. Epub 2014 Jul 23. PMID: 25052578. 18: Nguyen HM, Shier KL, Graber CJ. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2014 Apr;69(4):871-80. doi: 10.1093/jac/dkt450. Epub 2013 Nov 20. PMID: 24265230. 19: Adderson EE, Flynn PM, Hoffman JM. Efficacy and safety of cefepime in pediatric patients: a systematic review and meta-analysis. J Pediatr. 2010 Sep;157(3):490-5, 495.e1. doi: 10.1016/j.jpeds.2010.03.023. PMID: 20434167. 20: Bazan JA, Martin SI, Kaye KM. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime. Infect Dis Clin North Am. 2009 Dec;23(4):983-96, ix. doi: 10.1016/j.idc.2009.06.007. PMID: 19909894.